Related Experiment Video

Updated: Aug 18, 2026

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification
07:23

Culture of Murine Embryonic Metatarsals: A Physiological Model of Endochondral Ossification

Published on: December 3, 2016

Children with growth hormone deficiency. Intermittent treatment with somatropin and oxandrolone

C P Howard, H Takahashi, A B Hayles

    American Journal of Diseases of Children (1960)
    |April 1, 1981
    PubMed

    Insights

    This study evaluated growth hormone therapy for children with hypopituitarism. Somatropin alone and with oxandrolone significantly increased growth, but bone age acceleration requires further study.

    Area of Science:

    • Pediatric Endocrinology
    • Growth Hormone Therapy
    • Metabolic Disorders

    Background:

    • Human growth hormone deficiency (HGD) impacts childhood development.
    • Growth hormone therapy is a primary treatment for HGD.
    • Combination therapies are explored to optimize growth outcomes.

    Purpose of the Study:

    • To assess the efficacy of combined somatropin and oxandrolone in treating HGD.
    • To evaluate anthropometric and bone-age changes in children receiving combination therapy.

    Main Methods:

    • Twelve children with hypopituitarism were divided into two groups.
    • Treatment involved somatropin (0.1 IU/kg thrice weekly) and oxandrolone (0.1 mg/kg/day).
    • Anthropometric measurements and bone-age determinations were recorded over five 6-month periods.

    Main Results:

    • Both treatment groups achieved approximately 20 cm of growth over 30 months.
    • Somatropin significantly enhanced growth rate, both alone and combined with oxandrolone.
    • Oxandrolone addition may have mitigated the waning effect of somatropin therapy.

    Conclusions:

    • Combination therapy with somatropin and oxandrolone shows significant growth promotion in children with HGD.
    • Accelerated bone age suggests caution is needed for long-term oxandrolone use.
    • Further long-term studies are necessary to establish oxandrolone's role as an adjunct therapy.

    More Related Videos

    A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome08:20

    A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

    Published on: October 2, 2018

    Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

    Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

    Published on: August 9, 2024

    Related Concept Videos

    Nature and Nurture01:10

    Nature and Nurture

    Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
    Hormones and Bone Tissue01:17

    Hormones and Bone Tissue

    The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
    Hormones That Influence Osteoblasts and/or Maintain the Matrix
    Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
    Dosage Regimen: Fixed Dose01:01

    Dosage Regimen: Fixed Dose

    Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
    Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...